Following non-submission
AWMSG advice |
||
Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, ceftolozane/tazobactam (Zerbaxa®) cannot be endorsed for use within NHS Wales for the treatment of hospital-acquired pneumonia, including ventilator‑associated pneumonia in adults. Please refer to the AWMSG position statement on the appraisal of antimicrobial medicines. |
||
|
||
Medicine details |
||
Medicine name | ceftolozane/tazobactam (Zerbaxa®) | |
Formulation | 1 g/0.5 g powder for concentrate for solution for infusion | |
Reference number | 2182 | |
Indication | For the treatment of hospital-acquired pneumonia, including ventilator‑associated pneumonia in adults |
|
Company | Merck Sharp & Dohme Ltd | |
BNF chapter | Infections | |
Submission type | Non-submission | |
Status | Not endorsed (Statement of Advice) | |
Date of issue | 18/02/2020 | |
Further information AWMSG position statement on the appraisal of antimicrobial medicines |